GE Healthcare introduces the Biacore T100 Immunogenicity Package, software that supports screening, confirmation, and characterization of anti-drug antibodies during the preclinical and clinical drug development process. The Biacore T100 Immunogenicity Package, which supports data analyzed by a Biacore T100 label-free protein interaction analysis system, enables researchers to measure anti-drug antibodies even in the presence of excess amounts of drug. And by including guidelines and recommendations for development of immunogenicity assays, the software package also reduces assay development time. Tools included in the Package facilitate confirmation of positive samples, eliminate false positives due to drug depletion, and enable comprehensive characterization of immune response (e.g. determination of antibody isotype and anti-drug antibody binding stability).
Published in Drug Discovery & Development magazine: Vol. 11, No. 10, October, 2008, p.8.
Filed Under: Drug Discovery
